PURPOSE: Our goal was to evaluate use and associated costs of radiation therapy (RT) in the last month of life among those dying of cancer. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare linked databases to analyze claims data for 202,299 patients dying as a result of lung, breast, prostate, colorectal, and pancreas cancers from 2000 to 2007. Logistic regression modeling was used to conduct adjusted analyses of potential impacts of demographic, health services, and treatment-related variables on receipt of RT and treatment with greater than 10 days of RT. Costs were calculated in 2009 dollars. RESULTS: Among the 15,287 patients (7.6%) who received RT in the last month of life, its use was associated with nonclinical factors such as race, gender, income, and hospice care. Of these patients, 2,721 (17.8%) received more than 10 days of treatment. Nonclinical factors that were associated with greater likelihood of receiving more than 10 days of RT in the last 30 days of life included: non-Hispanic white race, no receipt of hospice care, and treatment in a freestanding, versus a hospital-associated facility. Hospice care was associated with 32% decrease in total costs of care in the last month of life among those receiving RT. CONCLUSION: Although utilization of RT overall was low, almost one in five of patients who received RT in their final 30 days of life spent more than 10 of those days receiving treatment. More research is needed into physician decision making regarding use of RT for patients with end-stage cancer.
PURPOSE: Our goal was to evaluate use and associated costs of radiation therapy (RT) in the last month of life among those dying of cancer. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare linked databases to analyze claims data for 202,299 patients dying as a result of lung, breast, prostate, colorectal, and pancreas cancers from 2000 to 2007. Logistic regression modeling was used to conduct adjusted analyses of potential impacts of demographic, health services, and treatment-related variables on receipt of RT and treatment with greater than 10 days of RT. Costs were calculated in 2009 dollars. RESULTS: Among the 15,287 patients (7.6%) who received RT in the last month of life, its use was associated with nonclinical factors such as race, gender, income, and hospice care. Of these patients, 2,721 (17.8%) received more than 10 days of treatment. Nonclinical factors that were associated with greater likelihood of receiving more than 10 days of RT in the last 30 days of life included: non-Hispanic white race, no receipt of hospice care, and treatment in a freestanding, versus a hospital-associated facility. Hospice care was associated with 32% decrease in total costs of care in the last month of life among those receiving RT. CONCLUSION: Although utilization of RT overall was low, almost one in five of patients who received RT in their final 30 days of life spent more than 10 of those days receiving treatment. More research is needed into physician decision making regarding use of RT for patients with end-stage cancer.
Authors: William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: George Rodrigues; Gregory M M Videtic; Ranjan Sur; Andrea Bezjak; Jeffrey Bradley; Carol A Hahn; Corey Langer; Keith L Miller; Benjamin J Moeller; Kenneth Rosenzweig; Benjamin Movsas Journal: Pract Radiat Oncol Date: 2011-04-08
Authors: Monica S Krishnan; Zachary Epstein-Peterson; Yu-Hui Chen; Yolanda D Tseng; Alexi A Wright; Jennifer S Temel; Paul Catalano; Tracy A Balboni Journal: Cancer Date: 2013-10-02 Impact factor: 6.860
Authors: Ya-Chen Tina Shih; Patricia A Ganz; Denise Aberle; Amy Abernethy; Justin Bekelman; Otis Brawley; James S Goodwin; Jim C Hu; Deborah Schrag; Jennifer S Temel; Lowell Schnipper Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Thomas A Buchholz; Ya-Chen Tina Shih Journal: J Oncol Pract Date: 2014-04-22 Impact factor: 3.840
Authors: Maryam Dosani; Scott Tyldesley; Brendan Bakos; Jeremy Hamm; Tim Kong; Sarah Lucas; Jordan Wong; Mitchell Liu; Sarah Hamilton Journal: Support Care Cancer Date: 2018-02-01 Impact factor: 3.603
Authors: Daniel E Spratt; Brandon R Mancini; James A Hayman; Thomas Boike; Lori J Pierce; Jean M Moran; Michael M Dominello; Mark Fireman; Kent Griffith; Shruti Jolly Journal: Int J Radiat Oncol Biol Phys Date: 2018-03-06 Impact factor: 7.038